Interní Med. 2018; 20(1): 14-18 | DOI: 10.36290/int.2018.004

Bronchial asthma diagnostics and therapy highlights

MUDr. Jakub Novosad, Ph.D., MUDr. Irena Krčmová, CSc.

Ústav klinické imunologie a alergologie, Fakultní nemocnice Hradec Králové, Univerzita Karlova v Praze,

Lékařská fakulta v Hradci Králové

Asthma bronchiale has been considered as chronic inflammatory airway disease characterized by airway hyperresponsivenessand remodeling for more than 100 years. The proof of a causal link between disease and inflammation is, among others, a clearclinical effect of maintenance antiinflammatory therapy, which dramatically improved the course and prognosis of asthma andminimized its lethality after its introduction in the second half of last century. However, there still remain almost 5% of patientssuffering from severe form of the disease prone to exacerbations and resistent to conventional therapy. These patients usuallyneed to be treated by systemic corticosteroids with plenty of adverse events. First time in 2015 have the international guidelinesproposed the use of biologicals or ultralong-acting muscarinic antagonists as first line ad-on therapy instead of the oral corticosteroidsinitiation. This approach improves the effectiveness and safety of treatment, as well as the comfort of patients significantly

Keywords: asthma bronchiale, inflammation, U-LAMA, biologicals

Published: March 1, 2018  Show citation